Investors Urged to Investigate Class Action Against Sarepta Therapeutics Due to Recent Controversies
Investor Alert: Pomerantz Law Firm and Sarepta Therapeutics' Controversies
Pomerantz LLP, a well-regarded law firm specializing in corporate and securities class action lawsuits, recently issued a critical announcement for investors regarding Sarepta Therapeutics, Inc. (NASDAQ: SRPT). A class action lawsuit has been filed against the company, following significant concerns about its marketing practices and the safety of its drug, ELEVIDYS.
This legal action came after Sarepta announced the tragic death of a young man suffering from Duchenne muscular dystrophy, who reportedly experienced acute liver failure after receiving treatment with ELEVIDYS. On March 18, 2025, the company released this news, causing its stock price to plummet by 27.44%, dropping $27.81 per share to a closing price of $73.54.
The situation worsened when, just weeks later, Sarepta faced further scrutiny. On April 4, 2025, the company disclosed that authorities in an EU member country had requested a meeting of an independent data monitoring committee to evaluate the earlier death. The firm also announced a halt in recruitment and dosing for certain clinical trials involving ELEVIDYS, leading to an additional drop in stock price, this time by 7.13%, closing at $54.43 per share.
By June 15, 2025, the situation had escalated yet again when Sarepta reported a second fatality linked to the drug due to acute liver failure, prompting the company to cease its clinical trial and temporarily suspend distribution of the drug to non-ambulatory patients. The consequences of this announcement were staggering, resulting in a 42.12% decline in Sarepta's stock price, bringing shares down to $20.94 the following day.
In an announcement dated June 24, 2025, the U.S. Food and Drug Administration (FDA) confirmed it was investigating these incidents following reports of two deaths associated with treatment from ELEVIDYS. The FDA's Safety Communication called into question the drug's safety profile, suggesting further regulatory actions could be on the horizon. Following this grim news, Sarepta's stock dipped again by 8.01%, to a closing price of $17.46.
Pomerantz LLP, founded by the prominent lawyer Abraham L. Pomerantz, is known for its historic commitment to fighting for victims of corporate wrongdoing and securities fraud. It has recovered extensive damages for clients over more than eight decades. The firm is currently seeking potential lead plaintiffs for the class action lawsuit against Sarepta. Prospective plaintiffs have until August 25, 2025, to make their voices heard.
Investors affected by these developments are encouraged to connect with Pomerantz LLP by reaching out to Danielle Peyton via email at [email protected] or by calling 646-581-9980, ext. 7980. It is advised that anyone interested includes their mailing address, contact number, and details on share purchases in their inquiries.
Sarepta’s recent challenges underline the serious implications that can arise from alleged corporate misconduct, especially in the highly sensitive pharmaceutical sector. Investors should remain vigilant and informed about their rights, as the outcome of this lawsuit may have lasting repercussions for both Sarepta Therapeutics and its shareholders.